Below you will find a list of the trials and studies being run by members of the Cambridge Pancreatic Cancer Centre. To learn more about pancreatic cancer clinical trials running across the UK, you can check out the Cancer Research UK trial finder page or the Pancreatic Cancer UK trial finder page.
Tissue/blood collection
MIPPaC: Understanding the mechanisms underlying weight loss in people with cancer by investigating changes to metabolism and the immune system
Learn MorePrecision-Panc: Advancing personalised medicine treatment strategies for pancreatic cancer
Learn MorePancrea_tive: Investigating tumour-stroma heterogeneity in human pancreatic cancer and pancreatic diseases
Learn MorePORTICO-Trans: A feasibility study looking at the immune system in tumours, comparing samples collected during surgery to those taken afterwards
Learn MoreLocally advanced
GRECO-2: A Randomised, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
Learn MoreOperable PDAC
Portico-SABR: Investigate the effects and safety of SABR treatment given to patients with operable pancreatic cancer prior to surgery to remove the tumour
Learn MoreMetastatic - 1st line
daNIS-2: A randomised, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
Learn MorePRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation
Learn MoreMetastatic - 2nd line and beyond
ATRiUM: A Phase I clinical trial looking at AZD6738 (ATR inhibitor) in combination with Gemcitabine
Learn MorePorcupine 2: A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care who have the RNF43 rearrangement.
Learn More